MorphoSys has regained rights from Celgene Corp to an experimental antibody for patients with multiple myeloma following the termination of a co-development and co-promotion agreement between the two companies.
France’s OSE Pharma SA, which is developing immunotherapies for cancer, has raised €21.1 million with an initial public offering of its shares on the Euronext stock exchange in Paris. The managers said the IPO was 3.6 times oversubscribed.
Rigontec GmbH, which is developing RNA-based immunotherapeutics for cancer and viral diseases, has reopened its Series A financing to include the new investors Forbion Capital Partners of the Netherlands and Sunstone Capital A/S of Denmark. Each invested €2.4 million.
Research by Douglas Melton of Harvard University and colleagues showing that insulin-producing pancreatic beta cells can be created in a laboratory has reached the stage of commercialisation with the launch of a new company aimed at bringing a cell therapy for diabetes into human trials.
A large impairment charge for a failed diabetes trial pushed Evotec AG into a loss for 2014 in what was otherwise a year of higher revenue and expanding business opportunities. Impairment charges of €8.5 million gave rise to an operating loss of €6.4 million for the year and a net loss of €7 million.
SkyePharma will more than double is net investment in research and development this year with plans to advance the clinical development of a new treatment for chronic obstructive pulmonary disease (COPD) as well as new drug delivery technologies.
Essex Woodlands, one of the world’s largest investors in pharmaceuticals and healthcare services, has teamed up with the serial entrepreneur Bryan Morton to launch a new UK-based speciality pharmaceutical business with a portfolio of marketed products that generated $27 million in sales in 2014.
Denmark-based Zealand Pharma A/S has announced its third management shake-up in a little over four months with the departure of Torsten Hoffmann, chief scientific officer, and Agneta Svedberg, chief operating officer.
A cardiovascular outcomes study of Lyxumia (lixisenatide) in high-risk patients with Type 2 diabetes has shown that the drug is not inferior, although not superior, to placebo, according to the study’s sponsor, Sanofi SA. The Phase 3b trial is called ELIXA.
Elias Zerhouni, head of research and development at Sanofi SA, used a gathering of regulatory officials in London on 18 March to appeal for more convergent standards for drug approvals. He argued that divergent standards among the drug authorities had created needless complexity for industry.